The position of renal denervation in treatment of hypertension: an expert consensus statement.

Consensus Hypertension Netherlands Patient care Sympathectomy

Journal

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 01 08 2022
pubmed: 25 8 2022
medline: 25 8 2022
entrez: 24 8 2022
Statut: ppublish

Résumé

Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood pressure (BP) targets. In order to improve BP control and lower the risk of subsequent cardiovascular events, renal sympathetic denervation (RDN) has been introduced and studied as a non-pharmacological approach. While early data on the efficacy of RDN showed conflicting results, improvements in treatment protocols and study design resulted in robust new evidence supporting the potential of the technology to improve patient care in hypertensive subjects. Recently, 5 randomised sham-controlled trials demonstrated the safety and efficacy of the technology. Modelling studies have further shown that RDN is cost-effective in the Dutch healthcare setting. Given the undisputable disease burden along with the shortcomings of current therapeutic options, we postulate a new, clearly framed indication for RDN as an adjunct in the treatment of hypertension. The present consensus statement summarises current guideline-recommended BP targets, proposed workup and treatment for hypertension, and position of RDN for those patients with primary hypertension who do not meet guideline-recommended BP targets (see central illustration).

Identifiants

pubmed: 36001280
doi: 10.1007/s12471-022-01717-4
pii: 10.1007/s12471-022-01717-4
pmc: PMC9807711
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

3-11

Informations de copyright

© 2022. The Author(s).

Références

Hypertension. 2017 Apr;69(4):678-684
pubmed: 28264922
Nephrol Dial Transplant. 2017 Sep 01;32(9):1440-1447
pubmed: 29059396
Am J Hypertens. 2018 Sep 11;31(10):1156-1163
pubmed: 30010694
N Engl J Med. 2014 Apr 10;370(15):1393-401
pubmed: 24678939
Circulation. 2022 Mar 15;145(11):847-863
pubmed: 35286164
Clin Res Cardiol. 2019 Dec;108(12):1331-1342
pubmed: 30941492
Medicine (Baltimore). 2017 Jan;96(4):e5641
pubmed: 28121920
Eur Heart J. 2019 Mar 1;40(9):743-751
pubmed: 30608521
Sci Rep. 2018 Oct 19;8(1):15505
pubmed: 30341333
Hypertension. 2013 Feb;61(2):457-64
pubmed: 23172929
Hypertension. 2010 Jul;56(1):10-6
pubmed: 20497993
Clin Res Cardiol. 2022 Nov;111(11):1256-1268
pubmed: 35851428
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
JACC Cardiovasc Interv. 2020 Dec 28;13(24):2922-2933
pubmed: 33357531
Lancet. 2018 Jun 9;391(10137):2335-2345
pubmed: 29803590
Circulation. 2019 Jan 29;139(5):590-600
pubmed: 30586691
J Am Heart Assoc. 2017 May 17;6(5):
pubmed: 28515119
Hypertension. 2021 Feb;77(2):529-536
pubmed: 33356403
Lancet. 2017 Nov 11;390(10108):2160-2170
pubmed: 28859944
Int J Cardiol. 2022 Apr 1;352:137-143
pubmed: 35176408
Lancet. 2020 May 2;395(10234):1444-1451
pubmed: 32234534
Lancet. 2015 May 16;385(9981):1957-65
pubmed: 25631070
Eur Heart J. 2019 Nov 1;40(42):3474-3482
pubmed: 30907413
J Cardiovasc Pharmacol. 2007 Nov;50(5):487-96
pubmed: 18030057
J Gen Intern Med. 2010 Apr;25(4):284-90
pubmed: 20131023
EuroIntervention. 2018 Dec 20;14(12):e1334-e1342
pubmed: 30222123
Circulation. 2019 Mar 17;:
pubmed: 30880441
Hypertension. 2016 Sep;68(3):707-14
pubmed: 27432864
J Hypertens. 2018 Aug;36(8):1614-1621
pubmed: 29846327
J Am Geriatr Soc. 2020 Mar;68(3):496-504
pubmed: 31840813
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Lancet. 2018 Jun 9;391(10137):2346-2355
pubmed: 29803589
J Hypertens. 2019 Nov;37(11):2290-2297
pubmed: 31335512
JACC Cardiovasc Interv. 2019 Jun 24;12(12):1109-1120
pubmed: 31221301
Circ Res. 2021 Apr 2;128(7):1080-1099
pubmed: 33793330
Neth J Med. 2014 Nov;72(9):449-54
pubmed: 25431389
JACC Cardiovasc Interv. 2020 Feb 24;13(4):471-484
pubmed: 32081241
Eur Heart J. 2015 Jan 21;36(4):219-27
pubmed: 25400162
Eur Heart J. 2011 Sep;32(17):2143-52
pubmed: 21471134
Lancet. 2009 Apr 11;373(9671):1275-81
pubmed: 19332353
Nat Rev Neurosci. 2006 May;7(5):335-46
pubmed: 16760914
J Am Coll Cardiol. 2012 Oct 2;60(14):1271-7
pubmed: 22981547
Neth J Med. 2019 Dec;77(10):349-355
pubmed: 31880270
Hypertens Res. 2008 Sep;31(9):1765-71
pubmed: 18971555
Hypertension. 2019 Jul 1;:HYPERTENSIONAHA11913081
pubmed: 31256723
Hypertension. 2020 Jul;76(1):80-86
pubmed: 32418497
Hypertension. 1997 Nov;30(5):1089-96
pubmed: 9369261
N Engl J Med. 2003 Jun 12;348(24):2407-15
pubmed: 12802026
Lancet. 2010 Dec 4;376(9756):1903-9
pubmed: 21093036
Hypertension. 2016 Aug;68(2):297-306
pubmed: 27296995
Hypertension. 2019 Mar;73(3):718-727
pubmed: 30661475
Eur Heart J. 2013 Oct;34(38):2940-8
pubmed: 23907142
EuroIntervention. 2020 May 20;16(1):89-96
pubmed: 32038027
Hypertens Res. 2022 Feb;45(2):221-231
pubmed: 34654905
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Medicine (Baltimore). 2019 Dec;98(49):e17825
pubmed: 31804305
Hypertension. 2005 Jul;46(1):156-61
pubmed: 15939805
Am J Physiol Renal Physiol. 2004 Jun;286(6):F1209-18
pubmed: 14969998
J Hypertens. 2014 Dec;32(12):2285-95
pubmed: 25255397
Hypertension. 2015 Feb;65(2):393-400
pubmed: 25403610
J Med Econ. 2015 Jan;18(1):76-87
pubmed: 25367314
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
EuroIntervention. 2015 May;11(1):110-6
pubmed: 25982653
Br J Clin Pharmacol. 2021 Oct;87(10):3721-3736
pubmed: 33733505
Lancet. 2021 Jun 26;397(10293):2476-2486
pubmed: 34010611
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
J Hypertens. 2011 Mar;29(3):610-8
pubmed: 21157368
Lancet. 2022 Apr 9;399(10333):1401-1410
pubmed: 35390320
Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):155-63
pubmed: 25648463

Auteurs

V J M Zeijen (VJM)

Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

A A Kroon (AA)

Department of Internal Medicine, Maastricht University Medical Center & Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.

B H van den Born (BH)

Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.

P J Blankestijn (PJ)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.

S C A Meijvis (SCA)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.

A Nap (A)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

E Lipsic (E)

Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

A Elvan (A)

Department of Cardiology, Isala Heart Center, Zwolle, The Netherlands.

J Versmissen (J)

Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

R J van Geuns (RJ)

Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

M Voskuil (M)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

P A L Tonino (PAL)

Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.

W Spiering (W)

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

J Deinum (J)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

J Daemen (J)

Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands. j.daemen@erasmusmc.nl.

Classifications MeSH